Neutrolis Announces New England Journal of Medicine Publication Demonstrating First Clinical Evidence for NET-Degrading Therapy in Severe, Treatment-Refractory Systemic Lupus Erythematosus (SLE) Caused by DNASE1L3 Deficiency
· neutrolis, inc.
AI Briefing
- • Neutrolis announces new England Journal of Medicine publication on NET-degrading therapy for severe SLE.
- • Investigational DNASE1L3 analog NTR-441 showed rapid clinical improvement in treatment-refractory SLE patient.
- • Treatment demonstrated first clinical evidence for NET-degrading therapy in SLE caused by DNASE1L3 deficiency.
Source Summary
Treatment with investigational DNASE1L3 analog NTR-441, which degrades neutrophil extracellular traps (NETs), resulted in rapid clinical improvement in a patient with treatment-refractory SLE
Advertisement